November 16, 2021
Dr. O'Dwyer and Dr. Schnall

From the Co-Chairs, November 2021

Practice-changing trial results in melanoma; Group and committee leadership updates; remembering a dear colleague and friend
November 16, 2021
Doctor patient skin exam

ASCO Highlights Practice-Changing Results in Melanoma

The phase III DREAMseq clinical trial provides strong evidence for starting treatment with combination immunotherapy then giving targeted therapy if the disease progresses in patients with BRAF V600 mutant metastatic melanoma
November 16, 2021
Bob Catalano headshot

Remembering Robert B. Catalano, PharmD

In October, the ECOG-ACRIN Cancer Research Group lost one of its most trusted senior counsellors, Regulatory Officer Robert B. Catalano, PharmD
November 16, 2021
Young patient and doctor with laptop

Now Enrolling: EAQ202 to Improve Adolescent and Young Adult Self-Reported Data

This pilot study is determining the feasibility and acceptability for adult and young adult participants patients between the ages of 18 and 39 in ECOG-ACRIN treatment trials to use the National Institutes of Health’s Patient-Reported Outcomes Measurement Information System (PROMIS®)
November 16, 2021
Evaluation Form

30 Member Networks and Programs Receive Commendations in 2021 for Outstanding Research Performance

In an annual evaluation, 30 member networks and programs met rigorous standards established by ECOG-ACRIN to indicate exemplary cancer research
November 16, 2021
Doctor conducing skin exam

Trial Spotlight: Ravi Amaravadi on the EA6191/BAMM2 Trial for Melanoma

This phase II randomized controlled trial is evaluating the effect of adding hydroxychloroquine to treatment with dabrafenib and trametinib in patients with advanced BRAF mutant melanoma
November 16, 2021
Rutgers Cancer Institute building

Institution Spotlight: Rutgers Cancer Institute of New Jersey

A Standing Main Member of ECOG-ACRIN since 1996
November 16, 2021
News in Brief

News in Brief, November 2021

Summaries and links to timely information about research results in medical journals, recognition of research leaders, and more